Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2000-10-27
2003-05-13
Housel, James (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S192100, C424S194100, C424S199100, C424S228100, C530S300000, C530S350000, C514S012200
Reexamination Certificate
active
06562346
ABSTRACT:
TECHNICAL AREA OF THE INVENTION
The invention relates to the activation of hepatitis C virus(HCV)-specific T cells. More particularly, the invention relates to the use of multiple HCV polypeptides, either alone or as fusions, to stimulate cell-mediated immune responses, such as to activate HCV-specific T cells.
BACKGROUND OF THE INVENTION
Hepatitis C virus (HCV) infection is an important health problem with approximately 1% of the world's population infected with the virus. Over 75% of acutely infected individuals eventually progress to a chronic carrier state that can result in cirrhosis, liver failure, and hepatocellular carcinoma. See Alter et al. (1992) N. Engl. J. Med. 327:1899-1905; Resnick and Koff. (1993) Arch. Intem. Med. 153:1672-1677; Seeff (1995) Gastrointest. Dis. 6:20-27; Tong et al. (1995) N. Engl. J. Med. 332:1463-1466.
Despite extensive advances in the development of pharmaceuticals against certain viruses like HIV, control of acute and chronic HCV infection has had limited success (Hooffiagle and di Bisceglie (1997) N. Engl. J. Med. 336:347-356). In particular, generation of a strong cytotoxic T lymphocyte (CTL) response is thought to be important for the control and eradication of HCV infections. Thus, there is a need in the art for effective methods of inducing strong CTL responses against HCV.
SUMMARY OF THE INVENTION
It is an object of the invention to provide reagents and methods for activating T cells which recognize epitopes of HCV polypeptides. This and other objects of the invention are provided by one or more of the embodiments described below.
The invention provides HCV proteins useful for activating HCV-specific T cells. One embodiment provides a fusion protein that consists essentially of an NS3, an NS4, and an NS5a polypeptide.
Another embodiment provides a fusion protein that consists essentially of an NS3, an NS4, an NS5a, and NS5b polypeptide of an HCV.
Still another embodiment of the invention provides a fusion protein comprising an NS3, an NS4, an NS5a and optionally an NS5b polypeptide of an HCV. One of the HCV polypeptides is derived from a different strain of HCV than the other polypeptides.
The invention also provides compositions comprising any of these fusion proteins and a pharmaceutically acceptable carrier.
Another embodiment provides a composition consisting essentially of an NS3, an NS4, and an NS5a polypeptide, or a composition consisting essentially of polynucleotides encoding the individual proteins.
Another embodiment provides a composition that consists essentially of an NS3, an NS4, an NS5a, and NS5b polypeptide of an HCV, or a composition consisting essentially of polynucleotides encoding the individual proteins.
Still another embodiment of the invention provides a composition consisting essentially of an NS3, an NS4, an NS5a and optionally an NS5b polypeptide of an HCV, or a composition consisting essentially of polynucleotides encoding the individual proteins. One of the HCV polypeptides or polynucleotides is derived from a different strain of HCV than the others.
Even another embodiment of the invention provides an isolated and purified polynucleotide which encodes a fusion protein consisting essentially of an NS3, an NS4, and an NS5a polypeptide of an HCV or a fusion protein consisting essentially of an NS3, an NS4, an NS5a, and an NS5b polypeptide of an HCV.
Yet another embodiment of the invention provides a composition comprising an isolated and purified polynucleotide which encodes a fusion protein consisting essentially of either an NS3, an NS4, and an NS5a polypeptide of an HCV or consisting essentially of an NS3, an NS4, an NS5a, and an NS5b polypeptide of an HCV. The composition also comprises a pharmaceutically acceptable carrier.
Another embodiment of the invention provides isolated and purified polynucleotide which encodes a fusion protein comprising an NS3, an NS4, and an NS5a polypeptide of an HCV in which one of the NS3, NS4, and NS5a polypeptides is derived from a different strain of HCV than the other two polypeptides. The invention also provides a composition comprising this polynucleotide and a pharmaceutically acceptable carrier.
Yet another embodiment of the invention provides an isolated and purified polynucleotide which encodes a fusion protein comprising an NS3, an NS4, an NS5a, and an NS5b polypeptide of an HCV. One of the polypeptides is derived from a different strain of HCV than the other polypeptides. The invention also provides a composition comprising this polynucleotide and a pharmaceutically acceptable carrier.
Even another embodiment of the invention provides a method of activating T cells which recognize an epitope of an HCV polypeptide. T cells are contacted with a fusion protein comprising an NS3, an NS4, and an NS5a polypeptide of an HCV. A population of activated T cells recognizes an epitope of the NS3, NS4, or NS5a polypeptide. Alternatively, T cells are contacted with a fusion protein comprising an HCV NS3, NS4, NS5a, NS5b polypeptide of an HCV. A population of activated T cells recognizes an epitope of the NS3, NS4, NS5a, or NS5b polypeptide.
The invention thus provides methods and reagents for activating T cells which recognize epitopes of HCV polypeptides. These methods and reagents are particularly advantageous for identifying epitopes of HCV polypeptides associated with a strong CTL response and for immunizing mammals, including humans, against HCV.
REFERENCES:
patent: 5683864 (1997-11-01), Houghton et al.
patent: 5747239 (1998-05-01), Wang et al.
patent: 5843752 (1998-12-01), Dasmahapatra et al.
patent: WO 97/44469 (1997-11-01), None
Nelson et al. J. Immunol. 1997, vol. 97, pp. 1473-1481.*
Koziel et al. J. Clin. Invest. 1995, vol. 96, pp. 2311-2321.*
Diepolder et al. J. Virol. 1997, vol. 71, pp. 6011-6013.*
Erikson et al. J. Immunol. 1993, vol. 151, pp. 4189-4199.*
Chien et al. J. Clinical Microb. 1999, vol. 37, pp. 1393-1397.*
Cerny et al. J. Clin. Invest. 1995, vol. 95, pp. 521-530.*
Bartenschlager et al. Intervirology 1997, vol. 40, pp. 378-393.*
Bartenschlager et al. J. Gene virol. 2000, vol. 81, pp. 1613-1548.*
Shintaro et al. Chem. Pharm. Bull. 1996, vol. 19, pp. 1254-1260.*
Minutelo et al. J. Exp. Med. 1993, vol. 178, pp. 17-25.*
Choe et al., “Enhanced Cellular Immunity to Hepatitis C Virus Nonstructural Proteins by Codelivery of Granulocyte Macrophage-Colony Stimulating Factor Gene in Intramuscular DNA Immunization,”Vaccine 17:1136-1144 (1999).
Houghton Michael
Paliard Xavier
Selby Mark
Blackburn Robert P.
Chiron Corporation
Harbin Alisa A.
Housel James
Li Bao Qun
LandOfFree
Activation of HCV-specific T cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Activation of HCV-specific T cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Activation of HCV-specific T cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3092229